New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2013
05:55 EDTBSX, BSX, X, X, TYC, TYC, TROW, TROW, PFE, PFE, PNR, PNR, BTU, BTU, NUE, NUE, NEE, NEE, IP, IP, ITW, ITW, HRS, HRS, HOG, HOG, F, F, EMC, EMC, LLY, LLY, DHR, DHR, GLW, GLW, VLO, VLOCompanies reporting Before the Market Open on Tuesday, January 29
Notable companies reporting before the opening bell on Tuesday include Boston Scientific (BSX), Corning (GLW), D.R. Horton (DHR), Danaher (DHR), Eli Lilly (LLY), EMC (EMC), Ford (F), Harley-Davidson (HOG), Harris (HRS), Illinois Tool Works (ITW), International Paper (IP), NextEra Energy (NEE), Nucor (NUE), Peabody Energy (BTU), Pentair (PNR), Pfizer (PFE), T. Rowe Price Group (TROW), Tyco International (TYC), United States Steel (X), and Valero Energy (VLO).
News For BSX;GLW;DHR;LLY;EMC;F;HOG;HRS;ITW;IP;NEE;NUE;BTU;PNR;PFE;TROW;TYC;X;VLO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
May 12, 2015
10:04 EDTXRumor: U.S. Steel strength attributed to takeover speculation
Subscribe for More Information
09:51 EDTDHRPall Corp. could be precursor to more Life Science deals, says Janney Capital
After The Wall Street Journal said Pall Corp. (PLL) is nearing a possible sale, naming Thermo Fisher (THO) and Danaher (DHR) as potential suitors, Janney Capital said it thinks dealmaking in the Life Sciences space won't stop with Pall, listing Repligen (RGEN), Bio-Techne (TECH) and VWR (VWR) as others in the industry that could see strategic bids emerge. The firm added that it expects that GE (GE), 3M (MMM), and private equity firms would also be involved in bidding in deals in the space.
09:47 EDTDHRPall Corp. bids due later this week, CNBC's Faber reports
David Faber on CNBC reported that bids for Pall Corp. (PLL) from Danaher (DHR) and Thermo Fisher (TMO) are due later this week. The auction is being led by Goldman Sachs (GS), Faber adds. He notes Danaher is likely going to offer an all-cash bid whereas Thermo Fisher will use up to $2B of equity. Faber said an offer price of $120 per share for Pall is likely the top of the range. The Wall Street Journal reported last night some of these details.
08:08 EDTXNow is the time to buy U.S. Steel, says Morgan Stanley
Subscribe for More Information
08:03 EDTPNRPentair has a conference call hosted by JPMorgan
Subscribe for More Information
07:46 EDTDHRDanaher has upper hand to acquire Pall, says Jefferies
After the Wall Street Journal reported that Pall Corp. (PLL) is near a possible sale and listed Danaher (DHR) and Thermo Fisher (TMO) as potential buyers, Jefferies says it believes Danaher has the upper hand in getting the deal done given its greater relative balance sheet capacity. The firm views both companies as logical buyers for Pall and notes a takeout bid of around $13B implies a share price of $120. The firm has a Buy rating on Pall.
06:30 EDTDHRPall volatility flat, Danaher, Thermo Fisher to submit final bids, WSJ reports
Subscribe for More Information
05:23 EDTBSXNevro announces filing of petitions for inter partes review by Boston Scientific
Subscribe for More Information
May 11, 2015
19:22 EDTDHRDanaher, Thermo Fisher to submit final bids for Pall, WSJ says
Danaher (DHR) and Thermo Fisher (TMO) are competing to acquire Pall (PLL), with final bids due later this week, reports The Wall Street Journal, citing people familiar with the matter. A deal could be valued at $13B or more, notes the Journal. Reference Link
17:36 EDTPFEAthersys down 10.1% after Pfizer notified that it will terminate agreement
Subscribe for More Information
17:34 EDTPFEAthersys receives notification that Pfizer will terminate agreement
Subscribe for More Information
17:13 EDTPNRPentair files automatic mixed securities shelf
Subscribe for More Information
16:33 EDTPFEPfizer takes minority interest in AM-Pharma, secures option to acquire company
AM-Pharma and Pfizer announced that Pfizer has acquired a minority equity interest in AM-Pharma and secured an exclusive option to acquire the remaining equity in the company. The option becomes exercisable upon completion of a Phase II trial of recAP in the treatment of Acute Kidney Injury related to sepsis. There are no drugs currently approved for this condition and the only treatment option is dialysis and supportive care. Results from the current Phase II trial for recAP are expected in the second half of 2016. Under the terms of the agreement, Pfizer has made an upfront payment of $87.5M for the minority equity interest and exclusive option, with additional potential payments of up to $512.5M upon option exercise and potential launch of any product that may result from this agreement. Other terms of the transaction were not disclosed. “Pfizer is committed to advancing the science to address the high unmet medical need in Acute Kidney Injury,” said Mikael Dolsten, M.D., Ph.D., president, Worldwide Research and Development at Pfizer. “Clinical data for recAP show the potential to uniquely address Acute Kidney Injury in the setting of sepsis, and we look forward to working with our partners at AM-Pharma as we aim to accelerate the development of recAP into a potential first-in-class treatment for patients.”
15:52 EDTNEEHawaiian Electric to host special shareholder meeting
Subscribe for More Information
15:37 EDTTYCApollo in talks to acquire ASG, combine with Protection 1, Reuters says
Subscribe for More Information
15:19 EDTLLYEli Lilly, BioNTech enter into research collaboration
Eli Lilly and BioNTech announced they have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body's own immune system to attack cancer cells and create possible new treatment options for cancer patients. Leveraging the scientific expertise between the two organizations, Lilly and BioNTech will collaborate to identify and validate novel tumor targets and their corresponding T cell receptors in one or more types of cancer. These tumor targets and TCRs may then be engineered and developed into potent and selective cancer therapies. Under the terms of the agreement, BioNTech will receive a $30M signing fee. For each potential medicine, BioNTech could receive over $300M in development, regulatory and commercial milestones. If successfully commercialized, BioNTech would also be eligible for tiered royalty payments up to double-digits. In addition, subject to the terms of the agreement, Lilly will make a $30M equity investment in BioNTech's subsidiary, Cell & Gene Therapies GmbH, which specializes in the research and development of TCR and chimeric antigen receptor immunotherapeutics. Further financial terms were not disclosed.
May 10, 2015
15:28 EDTFFord Venezuela to only sell vehicles in U.S. dollars, Reuters says
Ford's Venezuelan unit will sell vehicles exclusively in dollars beginning late June, Reuters reported Friday, citing two sources familiar with the situation. The country's currency control system has created difficulties converting vehicle sales to dollar revenue, noted Reuters. Reference Link
12:54 EDTNEEDuke, Edison, other utilities could return 8% annually, Barron's says
Shares of Duke Energy (DUK), Southern Company (SO), Consolidated Edison (ED), Edison International (EIX), PG&E (PCG), American Electric (AEP), Dominion (D), and NextEra Energy (NEE) could return 8% or more annually in coming years, Barron's contends in a feature article. Though utilities are sometimes seen as no-growth businesses, Barron's argues that infrastructure replacement projects, rate hikes, and dividend boosts make the sector look attractive. Reference Link
May 8, 2015
15:01 EDTTYCTyco management to meet with JPMorgan
Subscribe for More Information
09:03 EDTFBofA/Merrill auto analysts hold an analyst/industry conference call
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use